Natural toxins implicated in the development of Parkinson's disease

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 6, 2011, Pages 361-373

  Salama, Mohamed ^a   Arias Carrion, Oscar ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

animal models; natural toxins; Parkinson's disease; therapeutic testing

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANNONACIN; DOPAMINE; EPOXOMICIN; GLUCOSIDE; LEUCINE RICH REPEAT KINASE 2; NEUROTOXIN; OXIDOPAMINE; PARAQUAT; PESTICIDE; ROTENONE; STEROL;

ANNONA MURICATA; BORRELIA BURGDORFERI; CELL DEATH; DISEASE ASSOCIATION; EXPERIMENTAL MODEL; HELICOBACTER PYLORI; HUMAN; MYCOPLASMA PNEUMONIAE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NOCARDIA ASTEROIDES; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STREPTOMYCES VENEZUELAE;

EID: 82955164026     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611413004     Document Type: Article

References (79)

1. Abdulwahid Arif I. Ahmad Khan H. (2010) Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress. Toxicol Ind Health 26: 121–128.
2. Arias-Carrión O. Freundlieb N. Oertel W.H. Höglinger G.U. (2007) Adult neurogenesis and Parkinson's disease. CNS Neurol Disord Drug Targets 6: 326–335.
3. Arias-Carrión O. Yamada E. Freundlieb N. Djufri M. Maurer L. Hermanns G. et al. (2009) Neurogenesis in substantia nigra of Parkinsonian brains?. J Neural Transm Suppl 73: 279–285.
4. Barceloux D.G. (2009) Cycad seeds and chronic neurologic disease (Cycas species). Dis Mon 55: 353–360.
5. Barry D.P. Beaman B.L. (2007) Nocardia asteroides strain GUH-2 induces proteasome inhibition and apoptotic death of cultured cells. Res Microbiol 158: 86–96.
6. Beaman B.L. Tam S. (2008) An unusual murine behavior following infection with log-phase Nocardia asteroides type 6 strain GUH-2 (Nocardia cyriacigeorgica GUH-2). Microbes Infect 10: 840–843.
7. Bedford L. Paine S. Rezvani N. Mee M. Lowe J. Mayer R.J. (2009) The UPS and autophagy in chronic neurodegenerative disease: six of one and half a dozen of the other–or not?. Autophagy 5: 224–227.
8. Betarbet R. Sherer T.B. Greenamyre J.T. (2002) Animal models of Parkinson's disease. Bioessays 24: 308–318.
9. Blum D. Torch S. Lambeng N. Nissou M. Benabid A.L. Sadoul R. et al. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135–172.
10. Bove J. Zhou C. Jackson-Lewis V. Taylor J. Chu Y. Rideout H.J. et al. (2006) Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 60: 260–264.
11. Bradley W.G. Mash D.C. (2009) Beyond Guam: the cyanobacteria / BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph Lateral Scler 10(Suppl. 2): 7–20.
12. Caldwell K.A. Tucci M.L. Armagost J. Hodges T.W. Chen J. Memon S.B. et al. (2009) Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration. PloS ONE 4:e7227.
13. Caparros-Lefebvre D. Lees A.J. (2005) Atypical unclassifiable Parkinsonism on Guadeloupe: an environmental toxic hypothesis. Mov Disord 20(Suppl. 12): S114–S118.
14. Chen K.M. Craig U.K. Lee C.T. Haddock R. (2002) Cycad neurotoxin, consumption of flying foxes, and ALS / PDC disease in Guam. Neurology 59: 1664, author reply 1664-1665.
15. Cox P.A. Banack S.A. Murch S.J. (2003) Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci U S A 100: 13380–13383.
16. Cox P.A. Sacks O.W. (2002) Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology 58: 956–959.
17. Cucchiaroni M.L. Viscomi M.T. Bernardi G. Molinari M. Guatteo E. Mercuri N.B. (2010) Metabotropic glutamate receptor 1 mediates the electrophysiological and toxic actions of the cycad derivative beta-N-Methylamino-L-alanine on substantia nigra pars compacta DAergic neurons. J Neurosci 30: 5176–5188.
18. Dawson T.M. Ko H.S. Dawson V.L. (2010) Genetic animal models of Parkinson's disease. Neuron 66: 646–661.
19. Diaz-Corrales F.J. Colasante C. Contreras Q. Puig M. Serrano J.A. Hernandez L. et al. (2004) Nocardia otitidiscaviarum (GAM-5) induces Parkinsonian-like alterations in mouse. Braz J Med Biol Res 37: 539–548.
20. Ding H. Johnson G.V. (2008) The last tangle of tau. J Alzheimers Dis 14: 441–447.
21. Economo C.V. (1917) Encephalitis lethargica. Wiener Klinische Wochenschrift 30: 581–585.
22. Emborg M.E. (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods 139: 121–143.
23. Ensign J.C. Normand P. Burden J.P. Yallop C.A. (1993) Physiology of some actinomycete genera. Res Microbiol 144: 657–660.
24. Gasser T. (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 11: e22.
25. Haobam R. Sindhu K.M. Chandra G. Mohanakumar K.P. (2005) Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res 163: 159–167.
26. Hardy J. (2010) Genetic analysis of pathways to Parkinson disease. Neuron 68: 201–206.
27. Hasegawa M. Arai T. Akiyama H. Nonaka T. Mori H. Hashimoto T. et al. (2007) TDP-43 is deposited in the Guam Parkinsonism-dementia complex brains. Brain 130: 1386–1394.
28. Hirano A. Kurland L.T. Krooth R.S. Lessel S. (1961) Parkinsonism-dementia complex, an endemic disease on the island of Guam: 1. Clinical features. Brain 84: 642–661.
29. Hisahara S. Shimohama S. (2010) Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis 2011: 951709.
30. Höglinger G.U. Oertel W.H. Hirsch E.C. (2006) The rotenone model of Parkinsonism–the five years inspection. J Neural Transm Suppl 70: 269–272.
31. Höllerhage M. Matusch A. Champy P. Lombes A. Ruberg M. Oertel W.H. et al. (2009) Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp Neurol 220: 133–142.
32. Hyland K. Beaman B.L. LeWitt P.A. de Maggio A.J. (2000) Monoamine changes in the brain of BALB / c mice following sub-lethal infection with Nocardia asteroides (GUH-2). Neurochem Res 25: 443–448.
33. Jakowec M.W. Petzinger G.M. (2004) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 54: 497–513.
34. Jonasson S. Eriksson J. Berntzon L. Spacil Z. Ilag L.L. Ronnevi L.O. et al. (2010) Transfer of a cyanobacterial neurotoxin within a temperate aquatic ecosystem suggests pathways for human exposure. Proc Natl Acad Sci U S A 107: 9252–9257.
35. Karamyan V.T. Speth R.C. (2008) Animal models of BMAA neurotoxicity: a critical review. Life Sci 82: 233–246.
36. Kim S.T. Son H.J. Choi J.H. Ji I.J. Hwang O. (2010) Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease. Brain Res 1306: 176–183.
37. Kohbata S. Beaman B.L. (1991) L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice. Infect Immun 59: 181–191.
38. Konagaya M. Kato T. Sakai M. Kuru S. Matsuoka Y. Konagaya Y. et al. (2003) A clinical and pathological study of a Japanese case of Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex with family history. J Neurol 250: 164–170.
39. Kordower J.H. Kanaan N.M. Chu Y. Suresh Babu R. Stansell J. III Terpstra B.T. et al. (2006) Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 60: 264–268.
40. Lane E. Dunnett S. (2008) Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?. Psychopharmacology (Berl) 199: 303–312.
41. Lim K.L. Ng C.H. (2009) Genetic models of Parkinson disease. Biochim Biophys Acta 1792: 604–615.
42. Lobner D. Piana P.M. Salous A.K. Peoples R.W. (2007) Beta-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis 25: 360–366.
43. Lohle M. Reichmann H. (2010) Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci 289: 104–114.
44. Lotharius J. O'Malley K.L. (2000) The Parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275: 38581–38588.
45. Manning-Bog A.B. Langston J.W. (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res 11: 219–240.
46. Matsui H. Ito H. Taniguchi Y. Inoue H. Takeda S. Takahashi R. (2010) Proteasome inhibition in medaka brain induces the features of Parkinson's disease. J Neurochem 115: 178–187.
47. Mayer R.J. (2003) From neurodegeneration to neurohomeostasis: the role of ubiquitin. Drug News Perspect 16: 103–108.
48. McCormack A.L. Thiruchelvam M. Manning-Bog A.B. Thiffault C. Langston J.W. Cory-Slechta D.A. et al. (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10: 119–127.
49. McNaught K.S. Perl D.P. Brownell A.L. Olanow C.W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56: 149–162.
50. Meredith G.E. Totterdell S. Potashkin J.A. Surmeier D.J. (2008) Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14(Suppl. 2): S112–S115.
51. Morris H.R. Al-Sarraj S. Schwab C. Gwinn-Hardy K. Perez-Tur J. Wood N.W. et al. (2001) A clinical and pathological study of motor neurone disease on Guam. Brain 124: 2215–2222.
52. Murch S.J. Cox P.A. Banack S.A. (2004) A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci U S A 101: 12228–12231.
53. Obeso J.A. Rodriguez-Oroz M.C. Goetz C.G. Marin C. Kordower J.H. Rodriguez M. et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16: 653–661.
54. Pablo J. Banack S.A. Cox P.A. Johnson T.E. Papapetropoulos S. Bradley W.G. et al. (2009) Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand 120: 216–225.
55. Panneton W.M. Kumar V.B. Gan Q. Burke W.J. Galvin J.E. (2010) The neurotoxicity of DOPAL:behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PloS ONE 5: e15251.
56. Peng J. Stevenson F.F. Doctrow S.R. Andersen J.K. (2005) Superoxide dismutase / catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease. J Biol Chem 280: 29194–29198.
57. Pereira D. Garrett C. (2010) [Risk factors for Parkinson disease: an epidemiologic study]. Acta Med Port 23: 15–24.
58. Petroske E. Meredith G.E. Callen S. Totterdell S. Lau Y.S. (2001) Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP / probenecid treatment. Neuroscience 106: 589–601.
59. Potashkin J.A. Meredith G.E. (2006) The role of oxidative stress in the dysregulation of gene expression and protein metabolism in neurodegenerative disease. Antioxid Redox Signal 8: 144–151.
60. Prasad K. Tarasewicz E. Mathew J. Strickland P.A. Buckley B. Richardson J.R. et al. (2009) Toxicokinetics and toxicodynamics of paraquat accumulation in mouse brain. Exp Neurol 215: 358–367.
61. Rao S.D. Banack S.A. Cox P.A. Weiss J.H. (2006) BMAA selectively injures motor neurons via AMPA / kainate receptor activation. Exp Neurol 201: 244–252.
62. Richter F. Hamann M. Richter A. (2008) Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice. Brain Res 1188: 148–156.
63. Schneider D. Wink M. Sporer F. Lounibos P. (2002) Cycads: their evolution, toxins, herbivores and insect pollinators. Naturwissenschaften 89: 281–294.
64. Schober A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318: 215–224.
65. Schulz J.D. Hawkes E.L. Shaw C.A. (2006) Cycad toxins, Helicobacter pylori and Parkinsonism: cholesterol glucosides as the common denomenator. Med Hypotheses 66: 1222–1226.
66. Shaw C.A. Hoglinger G.U. (2008) Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?. Neuromolecular Med 10: 1–9.
67. Shen W.B. McDowell K.A. Siebert A.A. Clark S.M. Dugger N.V. Valentino K.M. et al. (2010) Environmental neurotoxin-induced progressive model of Parkinsonism in rats. Ann Neurol 68: 70–80.
68. Shimohama S. Sawada H. Kitamura Y. Taniguchi T. (2003) Disease model: Parkinson's disease. Trends Mol Med 9: 360–365.
69. Speciale S.G. (2002) MPTP: insights into Parkinsonian neurodegeneration. Neurotoxicol Teratol 24: 607–620.
70. Spencer P.S. Nunn P.B. Hugon J. Ludolph A.C. Ross S.M. Roy D.N. et al. (1987) Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237 (4814): 517–522.
71. Spencer P.S. Palmer V. Kisby G. (2009) The ALS / PDC syndrome of Guam and the cycad hypothesis. Neurology 72: 474–476, author reply 475-476.
72. Spencer P.S. Palmer V.S. Ludolph A.C. (2005) On the decline and etiology of high-incidence motor system disease in West Papua (southwest New Guinea). Mov Disord 20(Suppl. 12): S119–S126.
73. Tam S. Barry D.P. Beaman L. Beaman B.L. (2002) Neuroinvasive Nocardia asteroides GUH-2 induces apoptosis in the substantia nigra in vivo and dopaminergic cells in vitro. Exp Neurol 177: 453–460.
74. Tanner C.M. (2010) Advances in environmental epidemiology. Mov Disord 25(Suppl. 1): S58–S62.
75. Tillerson J.L. Miller G.W. (2003) Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 123: 189–200.
76. Trojanowski J.Q. Lee V.M. (2005) Pathological tau: a loss of normal function or a gain in toxicity?. Nat Neurosci 8: 1136–1137.
77. Ungerstedt U. (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5: 107–110.
78. Uversky V.N. (2004) Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318: 225–241.
79. Wood-Kaczmar A. Gandhi S. Wood N.W. (2006) Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12: 521–528.